Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock
數字之外：4位分析師討論y-mabs therapeutics股票
Diving into Analyst Ratings: An In-Depth...In the latest quarter, 4 analysts provided ratings for Y-mAbs Therapeutics (NASDAQ:YMAB), showcasing a mix of bullish and bearish perspectives.
在最新的季度裏，有4位分析師爲y-mabs therapeutics（納斯達克:YMAB）提供了評級，展示了看好和看淡觀點的混合。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中，您將找到他們最近的評級摘要，揭示了過去30天內情緒的變化，並將它們與前幾個月進行比較。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $22.0, along with a high estimate of $23.00 and a low estimate of $20.00. This upward trend is apparent, with the current average reflecting a 1.52% increase from the previous average price target of $21.67.
分析師們提供了更深入的見解，已經設定了12個月的價格目標，顯示平均目標爲22.0美元，高估值爲23.00美元，低估值爲20.00美元。這種上升趨勢是明顯的，當前的平均值反映了與之前的平均目標價格21.67美元相比增加了1.52%。
Diving into Analyst Ratings: An In-Depth...
深入探討分析師...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間